Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 20/20 | 0.68 |
| ▸ | PPARA | Q07869 | 15/20 | 0.68 |
| ▸ | PPARD | Q03181 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6640864 | 0.91 | PPARG (0.58) | PPARGPPARAPPARD | |
| SCHEMBL6621222 | 0.87 | PPARG (0.68) | PPARGPPARAPPARD | |
| SCHEMBL6622193 | 0.84 | PPARG (0.60) | PPARGPPARAPPARD | |
| SCHEMBL6625608 | 0.83 | PPARG (0.58) | PPARGPPARAPPARD | |
| SCHEMBL5726636 | 0.81 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL5726632 | 0.81 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL5727599 | 0.81 | PPARG (0.85) | PPARGPPARAPPARD | |
| SCHEMBL6626778 | 0.80 | PPARG (0.65) | PPARGPPARAPPARD | |
| SCHEMBL6626780 | 0.80 | PPARG (0.65) | PPARGPPARAPPARD | |
| SCHEMBL6637775 | 0.80 | PPARG (0.59) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6696474-B2 | SUCH AS 8-(5-METHYL-2-PHENYL-OXAZOL-4-YL)-2-PYRROL-1-YL-OCT-4-YNOIC ACID; NONINSULIN DEPENDENT DIABETES MELLITUS | WARNER LAMBERT CO. LLC. | 2004-02-24 | — | — | US | claimed |
| US-20030220381-A1 | ANTIDIABETIC AGENTS | WARNER-LAMBERT COMPANY, LLC | 2003-11-27 | — | — | US | claimed |
| EP-1490060-A1 | ANTIDIABETIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-12-29 | — | — | EP | disclosed |
| US-6696474-B2 | SUCH AS 8-(5-METHYL-2-PHENYL-OXAZOL-4-YL)-2-PYRROL-1-YL-OCT-4-YNOIC ACID; NONINSULIN DEPENDENT DIABETES MELLITUS | WARNER LAMBERT CO. LLC. | 2004-02-24 | — | — | US | disclosed |
| US-20030220381-A1 | ANTIDIABETIC AGENTS | WARNER-LAMBERT COMPANY, LLC | 2003-11-27 | — | — | US | disclosed |
| WO-2003082276-A1 | ANTIDIABETIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220381-A1 | ANTIDIABETIC AGENTS | GPR119, GCKR, GLP1R | PPARG 271/4885PPARA 488/4885PPARD 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.